Genetic engineering in non-human primates has long been limited by the need for virus-based gene delivery methods. Recently, researchers in Japan successfully used a nonviral system to introduce a transgene—that is, a gene that has been artificially inserted into an organism—into cynomolgus monkeys, which is a species of primate closely related to humans. The paper is published in the journal Nature Communications.
Small animal models such as mice do not fully replicate the complexity of human diseases, particularly in areas like infectious disease and neuropsychiatric disorders. This limitation has made non-human primates an essential model for biomedical research.
However, genetic modification of these primates has been challenging. For example, conventional virus-based methods require specialized containment facilities and are limited in terms of the size of transgenes that the viruses can carry. Also, these methods do not allow for precise selection of modified embryos before implantation.
A joint team of professors—Hajun Kim, Taejoon Kwon, and Joo Hun Kang—from the Department of Biomedical Engineering at UNIST has unveiled a novel diagnostic technique that utilizes artificially designed polymers known as peptide nucleic acid (PNA) as probes. The research is published in the journal Biosensors and Bioelectronics.
The fluorescence in situ hybridization (FISH) technique works by detecting fluorescent signals generated when probe molecules bind to specific genetic sequences in bacteria. This innovative FISH method employs two PNA molecules simultaneously. By analyzing the genomic sequences of 20,000 bacterial species, the research team designed PNA sequences that specifically target the ribosomal RNA of particular species.
The method is significantly faster and more accurate than traditional bacterial culture and polymerase chain reaction (PCR) analysis, and it holds promise for reducing mortality rates in critical conditions such as sepsis, where timely administration of antibiotics is crucial.
Professor Kwang-Hyun Cho’s research team has recently been highlighted for their work on developing an original technology for cancer reversal treatment that does not kill cancer cells but only changes their characteristics to reverse them to a state similar to normal cells. This time, they have succeeded in revealing for the first time that a molecular switch that can induce cancer reversal at the moment when normal cells change into cancer cells is hidden in the genetic network.
KAIST (President Kwang-Hyung Lee) announced on the 5th of February that Professor Kwang-Hyun Cho’s research team of the Department of Bio and Brain Engineering has succeeded in developing a fundamental technology to capture the critical transition phenomenon at the moment when normal cells change into cancer cells and analyze it to discover a molecular switch that can revert cancer cells back into normal cells.
A critical transition is a phenomenon in which a sudden change in state occurs at a specific point in time, like water changing into steam at 100℃. This critical transition phenomenon also occurs in the process in which normal cells change into cancer cells at a specific point in time due to the accumulation of genetic and epigenetic changes.
What makes us unique? Different from most, yet similar to a few? What shapes our physical, behavioral, and even mental makeup? The answer lies in our genes.
Passed from parents to their offspring, genes contain the information that specifies physical and biological traits.
But that’s not all. Genes are also responsible for diseases. Faulty genes can cause all kinds of issues that can manifest as birth defects, chronic diseases, or developmental problems.
As the race between U.S. and Chinese biotech companies heats up, the competition is particularly fierce in one field: CRISPR gene editing.
China has rapidly emerged as a global leader in CRISPR research. While much of the initial focus in the industry was on the use of the technology to develop cancer treatments, Chinese biotech firms have since moved to apply it to test therapies for rare diseases, including sickle cell disease and inherited eye disorders.
In many areas, Chinese companies have been more aggressive, pushing into diseases that their U.S. counterparts have shied away from, including in Duchenne muscular dystrophy and herpes virus. That willingness has raised eyebrows among some executives and academics in the U.S., while exciting others who fear the American regulators and companies have been too conservative.
Glioblastoma (GBM) is a highly aggressive and malignant brain tumor with a poor prognosis. Treatment options are limited, and the development of effective therapeutics is a major challenge. Here are some current and emerging therapeutic strategies for GBM:
Current Therapies 1. Surgery: Surgical resection is the primary treatment for GBM, aiming to remove as much of the tumor as possible. 2. Radiation Therapy: Radiation therapy is used to kill remaining tumor cells after surgery. 3. Temozolomide (TMZ): TMZ is a chemotherapy drug that is used to treat GBM, often in combination with radiation therapy. 4. Bevacizumab (Avastin): Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis.
Emerging Therapies 1. Immunotherapy: Immunotherapies, such as checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and cancer vaccines, aim to stimulate the immune system to attack GBM cells. 2. Targeted Therapies: Targeted therapies focus on specific molecular pathways involved in GBM, such as the PI3K/AKT/mTOR pathway. 3. Gene Therapy: Gene therapies aim to introduce genes that can help kill GBM cells or inhibit tumor growth. 4. Oncolytic Viruses: Oncolytic viruses are engineered to selectively infect and kill GBM cells. 5. CAR-T Cell Therapy: CAR-T cell therapy involves genetically modifying T cells to recognize and attack GBM cells. 6. Small Molecule Inhibitors: Small molecule inhibitors target specific proteins involved in GBM, such as EGFR, PDGFR, and BRAF.
Convergent engagement of neural and computational sciences and technologies are reciprocally enabling rapid developments in current and near-future military and intelligence operations. In this podcast, Prof. James Giordano of Georgetown University will provide an overview of how these scientific and technological fields can be — and are being — leveraged for non-kinetic and kinetic what has become known as cognitive warfare; and will describe key issues in this rapidly evolving operational domain.
James Giordano PhD, is the Pellegrino Center Professor in the Departments of Neurology and Biochemistry; Chief of the Neuroethics Studies Program; Co-director of the Project in Brain Sciences and Global Health Law and Policy; and Chair of the Subprogram in Military Medical Ethics at Georgetown University Medical Center, Washington DC. Professor Giordano is Senior Bioethicist of the Defense Medical Ethics Center, and Adjunct Professor of Psychiatry at the Uniformed Services University of Health Sciences; Distinguished Stockdale Fellow in Science, Technology, and Ethics at the United States Naval Academy; Senior Science Advisory Fellow of the SMA Branch, Joint Staff, Pentagon; Non-resident Fellow of the Simon Center for the Military Ethic at the US Military Academy, West Point; Distinguished Visiting Professor of Biomedical Sciences, Health Promotions, and Ethics at the Coburg University of Applied Sciences, Coburg, GER; Chair Emeritus of the Neuroethics Project of the IEEE Brain Initiative; and serves as Director of the Institute for Biodefense Research, a federally funded Washington DC think tank dedicated to addressing emerging issues at the intersection of science, technology and national defense. He previously served as Donovan Group Senior Fellow, US Special Operations Command; member of the Neuroethics, Legal, and Social Issues Advisory Panel of the Defense Advanced Research Projects Agency (DARPA); and Task Leader of the Working Group on Dual-Use of the EU-Human Brain Project. Prof. Giordano is the author of over 350 peer-reviewed publications, 9 books and 50governmental reports on science, technology, and biosecurity, and is an elected member of the European Academy of Science and Arts, a Fellow of the Royal Society of Medicine (UK), and a Fulbright Professorial Fellow. A former US Naval officer, he was winged as an aerospace physiologist, and served with the US Navy and Marine Corps.
The landmark advance builds on a 2013 study by the team, published in Science, which described the construction of the first GRO. In that study, the researchers demonstrated new solutions for safeguarding genetically engineered organisms and for producing new classes of synthetic proteins and biomaterials with “unnatural,” or human-created, chemistries.
Ochre is a major step toward creating a non-redundant genetic code in E. coli, specifically, which is ideally suited to produce synthetic proteins containing multiple, different synthetic amino acids.
In this episode of Becoming Young, Josh and Janae sit down with legendary longevity researcher Aubrey de Grey to explore the future of aging science and what it means for human lifespan. They dive deep into the latest breakthroughs in mTOR, rapamycin, senescence, and cellular rejuvenation, uncovering how cutting-edge research is redefining what’s possible for human healthspan.
Things we discussed…
The history of aging research and why scientists once believed aging was inevitable. Aubrey de Grey’s new mouse studies and what they reveal about reversing aging. Rapamycin, mTOR, and autophagy—how this pathway influences longevity. The role of senolytics and clearing aging cells to extend healthspan. What the future holds: Are we on the verge of radically extending human lifespan? This is a must-watch for anyone interested in biohacking, anti-aging science, and longevity breakthroughs.
Subscribe for more expert interviews on longevity, biohacking, and peak performance!
